最新ニュース Humana (NYSE:HUM) 株価情報

Humana

Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Earnings

News

Guidance

Health Care

Movers

General

水曜日、Humana Inc (NYSE:HUM) は、1株あたり6.96ドルの調整後EPSを報告し、これは1年前の1株あたり8.94ドルから減少しており、5.85ドルのコンセンサスを上回る結果となった。

保険大手ヒュマナの株価が下落　調整後FPS報告を受けて

Humana Inc

Humanscape

Humacyte Inc

Humble & Fume Inc

Hua Medicine

Humm Group Ltd

Humble Energy Inc

HUMMINGBIRD RES LTD ORD by Hummingbird Resources Ltd

Hummingbird Resources PLC

Humatech Inc

Shares of insurance and pharmacy benefit manager (PBM) companies such as Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) and CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) are trading lower Thursday, likely in reaction to UnitedHealth Group Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) disappointing fourth-quarter 2024 revenue results.
What To Know: UnitedHealth, the largest health insurer in the U.S., reported a revenue increase of 6.8% year-over-year to $100.8 billion, falling short of the consensus estimate of $101.76 billion.
UnitedHealth&#8217;s stock declined sharply, falling 6.04% to $510.59, as the earnings report highlighted concerns over its medical care ratio, which rose to 85.5% from 83.2% in 2023. This increase was attributed to factors such as Medicare funding reductions, member mix changes and the timing of Medicaid redeterminations.
UnitedHealth also reaffirmed its 2025 guidance, projecting $450 billion to $455 billion in revenue and adjusted EPS of $29.50 to $30.00.
The broader sector saw a ripple effect. The declines potentially reflect investor apprehension about sector-wide pressures, including reimbursement challenges and operational costs, spotlighted by UnitedHealth&#8217;s earnings report.
Price Actions: Closing Thursday, Centene stock dropped 0.44% to $62.87, CVS Health slid 0.15% to $51.96, Elevance Health fell 1.03% to $385.26 and Humana dropped 1.62% to $274.97 according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/01/43039835/dave-ramsey-breaks-down-how-a-40000-car-depreciates-by-16000-over-5-years-says-its-not-a-path-to-prosperity-even-on-an-80000-salary">Dave Ramsey Breaks Down How A $40,000 Car Depreciates By $16,000 Over 5 Years, Says It&#8217;s Not A Path To Prosperity, Even On An $80,000 Salary</a></li>
</ul>
Photo: Shutterstock.

Insurance

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Insurance, Pharmacy Benefit Manager Company Stocks Drop Following UnitedHealth's Q4 Revenue Miss: What's Going On?

Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) shares are trading lower by 3.0% to $271.13 during Thursday&#8217;s session following UnitedHealth Group's <a href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls">earnings report</a>, reflecting concerns about broader industry dynamics and potential impacts on similarly structured healthcare companies.
What To Know: Humana, like UnitedHealth, operates in the managed care and health insurance sectors, with a significant portion of its business tied to Medicare Advantage plans. 
Investors interpreted UnitedHealth's <a href="https://www.benzinga.com/pressreleases/25/01/b43022980/unitedhealth-group-reports-2024-results">higher medical care ratio</a>—indicating increased costs—as a potential warning sign for Humana, given shared exposure to rising healthcare expenses, Medicare reimbursement challenges, and Medicaid redetermination impacts.
Read Also: <a href="https://www.benzinga.com/news/25/01/43029982/whats-going-on-with-cvs-health-stock">What&#8217;s Going On With CVS Health Stock?</a>
Humana's business model, which relies heavily on serving seniors and offering value-based care, parallels UnitedHealth's Optum and Medicare Advantage segments. 
Concerns about rising medical costs or changes in member mix could easily extend to Humana, especially as both companies compete in an environment where margins are sensitive to regulatory and operational shifts. 
UnitedHealth's revenue miss, despite growth, likely heightened fears of similar headwinds for Humana, prompting investors to reassess risks across the sector.
Read Also: <a href="https://www.benzinga.com/general/social-media/25/01/43029066/meta-platforms-snap-shares-are-moving-lower-thursday-whats-going-on">Meta Platforms, Snap Shares Are Moving Lower Thursday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">Is HUM A Good Stock To Buy?</h2>
Wall Street analysts view Humana on the whole as Neutral, given the history of coverage over the past three months. Stephen Baxter from Wells Fargo in Humana is the most bearish, expecting a 25.06% fall in the stock in the coming year.
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Humana rose 0.08%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 14.78% over the past year.
A complete overview of how Wall Street views individual stocks is available <a href="https://www.benzinga.com/analyst-stock-ratings">here</a>, while real time updates on the latest analyst actions will be delivered via <a href="https://pro.benzinga.com">Benzinga PRO</a>. Try it for free.
HUM has a 52-week high of $455.53 and a 52-week low of $213.31.

What's Going On With Humana Stock?

WIIM

Shares of insurers and pharmacy benefit manager stocks are trading lower in possible reaction to UnitedHealth's quarterly revenue miss.

7 analysts have shared their evaluations of Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $285.43, with a high estimate of $308.00 and a low estimate of $253.00. Observing a 1.78% increase, the current average has risen from the previous average price target of $280.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1736978413_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$288.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$290.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$301.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$308.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$268.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$387.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$253.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Humana. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Humana's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Humana's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>Get to Know Humana Better</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Financial Milestones: Humana's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Humana displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 11.26%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.63%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Humana's ROE stands out, surpassing industry averages. With an impressive ROE of 2.8%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.96%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 0.74, Humana faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

A Glimpse Into The Expert Outlook On Humana Through 7 Analysts

Piper Sandler analyst Jessica Tassan maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and raises the price target from $270 to $288.

Price Target

Piper Sandler Maintains Neutral on Humana, Raises Price Target to $288

Traders adopted a cautious approach on Monday as they awaited two critical inflation reports due later this week, seeking clarity on Federal <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42953940/tuesdays-producer-inflation-report-could-stoke-market-volatility-as-fed-path-remains-unclear">Reserve interest rate policy. </a>
Additionally, the kickoff of earnings season, led by major banks on Wednesday, added to <a href="https://www.benzinga.com/markets">the market&#8217;s subdued tone.</a>
The S&amp;P 500 and Nasdaq 100 edged lower, continuing Friday&#8217;s downturn sparked by unexpectedly strong jobs data. The lack of &#8220;buy-the-dip&#8221; enthusiasm in the tech-heavy indices signaled lingering uncertainty among investors.
In contrast, the Dow Jones Industrial Average eked out a gain, buoyed by a rally in energy stocks. Rising oil prices provided a key lift, as West Texas Intermediate (WTI) crude oil surged over 3% to approach $78 per barrel — a level last seen in mid-August 2024. The spike followed U.S. sanctions on Russian crude exports announced on Friday, which shifted market expectations around supply and demand.
Treasury yields extended their ascent, with the 10-year yield climbing to 4.79% and the 30-year yield rising to 4.97%, reflecting heightened expectations for tighter monetary policy. Bank of America Securities launched a bombshell indicating rising risks towards a rate hike as the next Fed move.
Commodity markets saw mixed action. Gold endured its sharpest daily loss in nearly a month, falling more than 1% as rising yields weighed on the precious metal. Meanwhile, copper staged a modest rebound, gaining 0.8% after a 0.5% decline last Friday.
Cryptocurrencies faced renewed volatility, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) plunging 3% to dip below $92,000, briefly touching a two-month low. The ripple effects extended to crypto-linked equities: MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) slid more than 3%, while Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) dropped nearly 4%.
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day chg. %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,144.04</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,822.92</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,183.39</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,739.92</td>
<td>-0.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010625&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.1% lower to $579.98.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.7% to $422.03.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.6% to $504.44.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) dipped 0.3% to $216.19.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 2.3%; the&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul>
<li>Major oil &amp; gas giants rallying on Monday include Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>), up 5%, Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) up 3.9%, and Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) up 3.5%.</li>
<li>Health insurance companies surged after a government proposal suggested increased payments for Medicare Advantage plans in 2026, lifting sentiment across the sector.</li>
<li>Shares of Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) rose 7.8%, CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) followed closely with a 6.9% jump, while UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) saw a 4.8% increase.+</li>
<li>NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) dropped 2.7% to $132.19 as the AI chipmaker urged President-elect Donald Trump to oppose Biden administration regulations on AI technology. Meanwhile, HSBC cut its price target from $195 to $185 but reaffirmed its Buy rating.</li>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) plummeted 20% after projecting 2025 revenue of $1.5 billion to $2.5 billion, missing analysts&#8217; estimates of $2.92 billion. The company also announced it would fast-track its cost-cutting measures.</li>
<li>Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) fell 12% as authorities investigated whether equipment from its subsidiary, Southern California Edison, played a role in sparking the Hurst fire in Los Angeles.</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42948649/goldman-sachs-warns-of-90-oil-risk-trump-may-not-ease-sanctions-once-he-takes-office">Oil Could Hit $90, Goldman Sachs Says: &#8216;Trump May Not Ease Sanctions&#8217; On Russia</a></li>
</ul>
Photo: Ryan DeBerardinis via Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

COIN

SPDR Dow Jones Industrial Average ETF Trust

MRNA

MSTR

NVDA

Stocks Edge Down Ahead Of Key Inflation Reports, Crude Hits 5-Month High, Bitcoin Sinks: What's Driving Markets Monday?

CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) and UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock is moving higher on Monday. Here&#8217;s what you <a href="https://www.benzinga.com//node/42953047">need to know</a>.
What To Know: Shares of health insurance companies are trading higher after The Centers for Medicare and Medicaid Services proposed a rise to Medicare Advantage payments.
According to <a href="https://www.bloomberg.com/news/articles/2025-01-10/us-proposes-21-billion-boost-to-insurers-for-medicare-payments?embedded-checkout=true">Bloomberg</a>, the proposal suggests an average 4.3% increase in Medicare Advantage plan payments. If the plan is adopted, it could lead to an additional $21 billion in payments for 2026 compared to the expected 2025 figures.
This follows concerns from health insurers that current rates are too low to cover medical expenses. 
"While rates in recent years have been considered insufficient" by Medicare insurers, "there is some optimism that rates could improve under a Trump CMS," said JPMorgan analyst Lisa Gill told Bloomberg.
Health insurance companies offering Medicare Advantage plans receive direct payments from the federal government to cover beneficiaries. An increase in these payments could drive higher revenue and improved margins, likely boosting investor confidence in these companies.
Notably, CVS, Humana and UnitedHealth sold more than half of the Medicare Advantage plans in 2024, as reported by KFF. Additionally, the Medicare Payment Advisory Commission noted that Medicare Advantage covered more than half of Medicare beneficiaries in 2023.
The U.S. is expected to spend $9.2 trillion over the next decade on payments to private Medicare plans.
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42953757/whats-going-on-with-trump-media-technology-group-stock-4">What&#8217;s Going On With Trump Media &amp; Technology Group Stock?</a>
Price Action: At the time of publication, CVS stock is trading 7.43% higher at $51.56, Humana shares are trading 7.38% higher at $289.98 and UnitedHealth stock is moving 4.37% higher at $543.48, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

What's Going On With CVS, Humana and UnitedHealth Shares Monday?

Investors with a lot of money to spend have taken a bullish stance on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HUM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 20 uncommon options trades for Humana.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $264,753, and 13 are calls, for a total amount of $937,980.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $220.0 to $500.0 for Humana over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Humana's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Humana's significant trades, within a strike price range of $220.0 to $500.0, over the past month.
<h3>Humana 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736788522_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$9.2</td>
<td>$5.7</td>
<td>$6.2</td>
<td>$500.00</td>
<td>$308.7K</td>
<td>7.8K</td>
<td align="right">544</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$55.2</td>
<td>$53.2</td>
<td>$54.5</td>
<td>$260.00</td>
<td>$70.8K</td>
<td>25</td>
<td align="right">14</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$50.7</td>
<td>$44.7</td>
<td>$47.0</td>
<td>$300.00</td>
<td>$70.5K</td>
<td>143</td>
<td align="right">15</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$11.5</td>
<td>$9.8</td>
<td>$11.5</td>
<td>$280.00</td>
<td>$64.4K</td>
<td>1.7K</td>
<td align="right">147</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$82.6</td>
<td>$80.3</td>
<td>$80.3</td>
<td>$220.00</td>
<td>$64.2K</td>
<td>27</td>
<td align="right">8</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Following our analysis of the options activities associated with Humana, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Humana</h3>
<ul>
<li>With a trading volume of 975,075, the price of HUM is up by 7.0%, reaching $287.88.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 29 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Humana</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $295.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Humana, targeting a price of $290. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Humana, which currently sits at a price target of $301. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Humana options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Market Whales and Their Recent Bets on HUM Options

Shares of health insurers are trading higher after The Centers for Medicare & Medicaid Services proposed a rise to Medicare Advantage payments.

U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Monday.
Shares of Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) rose sharply during Monday's session after Johnson &amp; Johnson agreed to acquire the company for $132.00 per share in cash for a total equity value of <a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal">approximately $14.6 billion</a>.
With this agreement, Johnson &amp; Johnson adds Intra-Cellular Therapies' Caplyta (lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate.
Intra-Cellular Therapies shares jumped 34.6% to $127.62 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares jumped 35.5% to $7.52. On Friday, Sage Therapeutics confirmed that Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.</li>
<li>Standard BioTools Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NYSE">LAB</a>) gained 24% to $2.0250 after the company announced preliminary fourth-quarter and FY24 financial results.</li>
<li>LSB Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXU#NYSE">LXU</a>) rose 21% to $9.00 after Piper Sandler upgraded the stock from Underweight to Overweight and raised its price target from $9 to $11.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) gained 17% to $2.86.</li>
<li>SI-BONE, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) rose 14.1% to $15.66 after the company announced preliminary revenue for the fourth quarter and full year 2024.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) climbed 13.9% to $8.85.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) rose 13% to $39.92.</li>
<li>Radiopharm Theranostics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) climbed 12.2% to $6.00.</li>
<li>Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) gained 11.4% to $6.93 as the company announced fourth-quarter preliminary revenue at high end of guidance.</li>
<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) rose 10.4% to $96.43 after the company reported a year-over-year increase in FY24 AYVAKIT revenue results.</li>
<li>Radiopharm Theranostics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) gained 10.3% to $5.90. Radiopharm Theranostics announced it will execute a private placement and will raise $5 million in proceeds.</li>
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) gained 8.5% to $37.15 amid a report that Cleveland-Cliffs will partner with Nucor to make a potential bid for the company.</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) gained 6.6% to $286.90.</li>
<li>CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) rose 6.3% to $94.35. Piper Sandler analyst Charles Neivert upgraded CF Industries Holdings from Underweight to Overweight and raised the price target from $79 to $105.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42947348/tesla-to-rally-around-9-here-are-10-top-analyst-forecasts-for-monday">Tesla To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

Intraday Update

Trading Ideas

BIIB

BPMC

CRML

ITCI

RADX

SAGE

SIBN

Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday

KeyBanc Capital Markets writes that Healthcare Services stocks are expected to see significant changes in 2025.
Strong volumes, increased enrollment in health insurance exchanges (HIX) and Medicaid-directed payment programs (DPPs) will likely benefit hospitals.
However, the uncertain policies under Trump may still affect investor confidence.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/07/39803259/uhs-acadia-healthcare-navigate-scrutiny-amid-safety-concern-allegations-at-psychiatric-hospitals-o" rel="noreferrer noopener">UHS, Acadia Healthcare Navigate Scrutiny Amid Safety Concern Allegations At Psychiatric Hospitals, Operating As Nonprofit</a>
Medicare Advantage (MA) managed care organizations (MCOs) are still facing higher costs, but the funding situation for MA could improve in the first half of 2025, offering a clearer path for profit recovery in 2026 and beyond.
As the industry approaches 2025, KeyBanc analyst Matthew Gillmor says he prefers stocks tied to higher patient volumes that are somewhat protected from policy changes.
The analyst expects patient volumes to stay high due to strong HIX enrollment and ongoing post-COVID trends, which will benefit hospitals&#8217; earnings but may limit earnings growth for MCOs.
KeyBanc highlights that volume comparisons will be tough and will monitor proprietary data for trend changes.
Healthcare policy will be a key focus in the first half of 2025, with HIX subsidies and Medicaid DPP being important for hospitals and the 2026 MA rate notice as well as Humana Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) lawsuit being key for MCOs.
KeyBanc expects the policy situation for MA MCOs to improve by April, with UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) being the top choice to benefit from this. Additionally, sentiment around behavioral hospitals, particularly Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>), is likely at its lowest.
KeyBanc has upgraded Acadia Healthcare to Overweight from Sector Weight with a price target of $70, citing meaningful higher inflection during 2025 as investors gain visibility into the potential 2026 EBITDA acceleration and valuation returns to historical ranges.
Acadia&#8217;s stock lagged behind the market in 2024 due to <a href="https://www.benzinga.com/news/large-cap/24/09/41067826/federal-investigations-continue-for-psychiatric-hospital-chain-operator-acadia-healthcare-even-aft" target="_blank" rel="noreferrer noopener">external challenges</a> and rising startup expenses, which hurt EBITDA in 2024 and 2025. The analyst believes these issues will improve by 2026, as new beds added in 2024-2025 start to pay off and the increase in startup losses during 2025 slows down or stabilizes.
Price Action: ACHC stock is up 1.45% at $45.50 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42856421/from-earth-to-the-moon-intuitive-machines-and-nokia-launch-4glte-network" target="_blank" rel="noreferrer noopener">Intuitive Machines Finalizes Lunar Lander Installation, Paving The Way For Nokia Network On The Moon</a></li>
</ul>
Courtesy photo

Upgrades

ACHC

Psychiatric Hospital Operator Acadia Healthcare Earns Upgrade Amid Expected Recovery In 2025

Financial giants have made a conspicuous bearish move on Humana. Our analysis of options history for Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) revealed 10 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $113,577, and 7 were calls, valued at $382,185.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $250.0 and $320.0 for Humana, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Humana stands at 397.5, with a total volume reaching 378.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Humana, situated within the strike price corridor from $250.0 to $320.0, throughout the last 30 days.
<h3>Humana Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736192727_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$66.8</td>
<td>$60.2</td>
<td>$64.0</td>
<td>$280.00</td>
<td>$128.0K</td>
<td align="right">82</td>
<td align="right">20</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$31.2</td>
<td>$30.3</td>
<td>$30.6</td>
<td>$250.00</td>
<td>$76.5K</td>
<td align="right">168</td>
<td align="right">25</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$41.9</td>
<td>$39.1</td>
<td>$39.79</td>
<td>$305.00</td>
<td>$51.7K</td>
<td align="right">29</td>
<td align="right">13</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$10.5</td>
<td>$10.3</td>
<td>$10.3</td>
<td>$320.00</td>
<td>$48.4K</td>
<td align="right">18</td>
<td align="right">55</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.25</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$290.00</td>
<td>$42.0K</td>
<td align="right">562</td>
<td align="right">230</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
After a thorough review of the options trading surrounding Humana, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Humana</h3>
<ul>
<li>With a volume of 950,088, the price of HUM is up 1.23% at $265.71. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 17 days.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $295.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Humana with a target price of $301. 
&#x2A; An analyst from Truist Securities persists with their Hold rating on Humana, maintaining a target price of $290. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Humana, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Behind the Scenes of Humana's Latest Options Trends

Truist Securities analyst David Macdonald maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and raises the price target from $260 to $290.

Truist Securities Maintains Hold on Humana, Raises Price Target to $290

Wall Street is watching for developments in Washington, D.C. Friday after <a href="https://www.benzinga.com/24/12/42607744/house-rejects-trump-endorsed-backup-plan-to-prevent-government-shutdown-and-suspend-debt-limit-lawmakers-chant-he">Thursday's failed attempt</a> to avert a government shutdown. Some stocks remain wobbly as the day wears on and a midnight deadline approaches. 
What Happened: The House turned down a contingency plan proposed by Speaker Mike Johnson (R-La) only hours before the vote Thursday. The proposal failed to secure the necessary two-thirds majority. 
Backed by President-elect Donald Trump, the funding bill ran into trouble mainly from Democrats due to its inclusion of a two-year debt limit suspension. The bill would have maintained government funding&nbsp;at existing levels through mid-March, suspended the debt limit&nbsp;for two years and allocated approximately&nbsp;$100 billion in disaster relief&nbsp;and about $10 billion for&nbsp;farmer economic assistance.
<h2 class="wp-block-heading">Market Movement, Sectors Affected </h2>
Defense Sector: Companies in the defense industry, such as Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) , Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) and L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) often depend heavily on government contracts. During a shutdown, delays in contract awards and payments can occur, potentially impacting cash flow and stock performance.
Health Care Sector: Firms that receive substantial revenue from government health care programs, like Medicare and Medicaid, might experience payment delays during the shutdown. This could affect companies such as UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) and Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).
Aerospace Sector: Aerospace companies that rely on federal contracts or regulatory approvals could face delays, potentially affecting their operations and stock prices. These stocks include Lockheed Martin and Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)
Consumer, Retail Sectors: A shutdown can lead to furloughs for federal employees, resulting in delayed paychecks. This reduction in disposable income may decrease consumer spending over the holidays, adversely affecting retail companies and consumer goods manufacturers.
Financial Sector: Government shutdowns can delay economic reports and data releases, creating uncertainty in financial markets. Naturally, this uncertainty could lead to increased market volatility, impacting financial institutions and investment firms.
<h2 class="wp-block-heading">Holiday Travelers, Take Note</h2>
With the busy holiday season upon us and the Transportation Security Administration expecting to screen up to 40 million air travelers in the coming weeks, air traffic controllers and essential airport workers could be doing their jobs without the prospect of a paycheck.
Before the Capitol moved closer to a shutdown, the AAA predicted over 119 million people would hit the roads over the holidays, <a href="https://www.nytimes.com/2024/12/20/travel/government-shutdown-travel.html">noted</a> the NY Times. If no funding solution is reached by midnight, the already crowded highways could be even more so as planes and trains fill up or, worse, face cancellations. No matter what happens in D.C., Amtrak is expected to keep the trains running on schedule.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42619788/market-volatility-halts-on-soft-inflation-data-yet-traders-remain-wary-of-fighting-the-fed-10-etfs-moving-friday">Market Volatility Halts On Soft Inflation Data, Yet Traders Remain Wary Of Fighting The Fed: 10 ETFs Moving Friday</a></li>
</ul>
Photo via Shutterstock

Equities

Government

Politics

Government Shutdown Threat: Holiday Travel, Paychecks Could Face Delays If No Deal Reached

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Biotech

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

Ratings for Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) were provided by 21 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">16</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $278.95, with a high estimate of $395.00 and a low estimate of $247.00. A decline of 22.03% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1734465644_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Humana is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$301.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$308.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$268.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$387.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$253.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$260.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$364.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Lance Wilkes</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$308.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$261.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$253.00</td>
<td>$419.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$274.00</td>
<td>$392.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$250.00</td>
<td>$349.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Kevin Fischbeck</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$247.00</td>
<td>$376.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$250.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$395.00</td>
<td>$395.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Humana. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Humana's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Humana's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>Discovering Humana: A Closer Look</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Breaking Down Humana's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Humana showcased positive performance, achieving a revenue growth rate of 11.26% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Humana's net margin is impressive, surpassing industry averages. With a net margin of 1.63%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Humana's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.8%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Humana's ROA stands out, surpassing industry averages. With an impressive ROA of 0.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Humana's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.74, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Humana Stands With Analysts

Investors with a lot of money to spend have taken a bearish stance on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HUM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 54 uncommon options trades for Humana.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.
Out of all of the special options we uncovered, 38 are puts, for a total amount of $4,018,250, and 16 are calls, for a total amount of $699,769.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $200.0 to $290.0 for Humana over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Humana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Humana's substantial trades, within a strike price spectrum from $200.0 to $290.0 over the preceding 30 days.
<h3>Humana Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734463821_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.4</td>
<td>$3.1</td>
<td>$3.19</td>
<td>$220.00</td>
<td>$647.5K</td>
<td>1.1K</td>
<td>2.0K</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.5</td>
<td>$1.45</td>
<td>$2.6</td>
<td>$245.00</td>
<td>$527.8K</td>
<td>2.1K</td>
<td>2.1K</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$21.8</td>
<td>$19.0</td>
<td>$20.4</td>
<td>$260.00</td>
<td>$306.0K</td>
<td>1.4K</td>
<td>799</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$22.3</td>
<td>$20.8</td>
<td>$20.4</td>
<td>$260.00</td>
<td>$255.0K</td>
<td>1.4K</td>
<td>926</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$22.2</td>
<td>$20.2</td>
<td>$21.0</td>
<td>$260.00</td>
<td>$210.0K</td>
<td>1.4K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Following our analysis of the options activities associated with Humana, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Humana</h3>
<ul>
<li>With a trading volume of 2,664,992, the price of HUM is down by -8.58%, reaching $238.12.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 37 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Humana</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $301.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Humana with a target price of $301. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Humana options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Smart Money Is Betting Big In HUM Options

Wall Street began Tuesday&#8217;s session on a weaker note, with major indices slipping after November's robust retail sales report reignited investor concerns that the Federal Reserve might hold back interest <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42514008/fed-poised-to-cut-interest-rates-by-0-25-this-week-heres-why-your-focus-should-shift-to-other-signals">rate cuts next year. </a>
The data, which underscored resilient consumer spending heading into the holiday season, added a fresh layer of uncertainty to the Fed's future rate path ahead of Wednesday&#8217;s highly awaited December Federal Open Market Committee meeting.
Retail sales surged 0.7% last month, outperforming consensus estimates of a 0.5% increase and marking a notable acceleration from October's <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42529956/november-retail-sales-soar-to-11-month-highs-indicate-strong-holiday-season">upwardly revised 0.5% gain. </a>
On an annual basis, sales climbed 3.8%, hitting their fastest pace since December 2023. A significant portion of the strength came from auto sales, which soared 2.6% on a monthly basis and by a robust 6.5% year-over-year, highlighting consumers' willingness to make big-ticket purchases in the fourth quarter of the year.
Spending was also robust in other categories. Nonstore retailers, driven by e-commerce activity, posted a 1.8% monthly gain, reflecting the growing dominance of online shopping as the holiday season commenced. Sporting goods, hobby, and book stores registered a 0.9% uptick, showing steady demand for discretionary items.
<h3 class="wp-block-heading">Market Reaction: Pressure Builds On Equities</h3>
The stronger-than-expected data put equity markets under pressure, as investors recalibrated their expectations for the Fed's next moves. 
The S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – and Dow Jones Industrial Average both fell 0.7%, while the Nasdaq 100 – tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – slid 0.8%, weighed down by weakness in the chip sector. 
Semiconductor stocks led the downturn amid renewed geopolitical tensions after reports surfaced that China is broadening antitrust scrutiny on U.S. chipmakers&#8217; acquisitions in recent years. Last week, Beijing opened an investigation on U.S. chip giant Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 2019 acquisition of Mellanox Technologies.
<h3 class="wp-block-heading">Investors Face Fed Uncertainty</h3>
The robust retail sales data is the latest in a series of reports—alongside <a href="https://www.benzinga.com/news/treasuries/24/12/42460477/producer-inflation-rises-more-than-expected-to-3-in-november-cast-shadow-on-further-disinflation-progress">hotter-than-expected inflation prints</a> and upbeat <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42511277/us-services-sector-booms-at-fastest-pace-since-october-2021-business-activity-leaps-to-over-two-year-highs">December Purchasing Managers&#8217; Index surveys</a>—that challenge the case for aggressive rate cuts next year.
While a 25-basis-point reduction at the Fed's policy meeting this week is widely anticipated, the central bank's outlook for 2025 remains in question.
Fed fund futures now suggest an 80% chance the Fed will hold rates steady at its January meeting, while expectations for a March rate cut have softened, with odds slipping to 58% from 60% a day earlier.
Betting-implied odds from CFTC-regulated Kalshi continue to suggest an elevated 92% probability of four cuts next year, yet financial markets now imply only three rate cuts. 
<h3 class="wp-block-heading">Top 5 S&amp;P 500 Performers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Price ($)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>SolarEdge Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>)</td>
<td>14.35</td>
<td>+16.57%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>26.24</td>
<td>+3.88%</td>
</tr>
<tr>
<td>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>68.65</td>
<td>+3.26%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>475.11</td>
<td>+2.82%</td>
</tr>
<tr>
<td>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>42.81</td>
<td>+2.37%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Top 5 S&amp;P 500 Losers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Price ($)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>234.36</td>
<td>-6.29%</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>21.00</td>
<td>-4.35%</td>
</tr>
<tr>
<td>Constellation Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>231.09</td>
<td>-3.43%</td>
</tr>
<tr>
<td>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)</td>
<td>252.18</td>
<td>-3.33%</td>
</tr>
<tr>
<td>NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</td>
<td>91.18</td>
<td>-3.25%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Top 5 Nasdaq 100 Performers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Price ($)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Super Micro Computer Inc. (NASDAQ: SMCI9 </td>
<td>34.47</td>
<td>+3.08%</td>
</tr>
<tr>
<td>Tesla Inc.</td>
<td>472.84</td>
<td>+2.33%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/regn#NASDAQ">REGN</a>)</td>
<td>740.51</td>
<td>+2.24%</td>
</tr>
<tr>
<td>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)</td>
<td>738.86</td>
<td>+2.22%</td>
</tr>
<tr>
<td>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXP#NASDAQ">NXP</a>)</td>
<td>222.95</td>
<td>+2.21%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Top 5 Nasdaq 100 Losers</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Price ($)</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>)</td>
<td>114.10</td>
<td>-8.52%</td>
</tr>
<tr>
<td>Broadcom</td>
<td>234.15</td>
<td>-6.37%</td>
</tr>
<tr>
<td>Nvidia</td>
<td>127.15</td>
<td>-3.65%</td>
</tr>
<tr>
<td>Constellation Energy</td>
<td>231.04</td>
<td>-3.45%</td>
</tr>
<tr>
<td>SiriusXM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>)</td>
<td>22.02</td>
<td>-2.76%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42531373/financial-stocks-near-record-year-could-trump-deregulation-fuel-bigger-gains-in-2025">Financial Stocks Near Record Year: Could Trump Deregulation Fuel Bigger Gains In 2025?</a></li>
</ul>
Image created using photos from Shutterstock.

Retail Sales

ASML

AVGO

MRVL

REGN

SEDG

SIRI

TSLA

Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts

Morgan Stanley analyst Erin Wright maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and raises the price target from $288 to $301.

Morgan Stanley Maintains Equal-Weight on Humana, Raises Price Target to $301

Deep-pocketed investors have adopted a bullish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Humana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 33% bearish. Among these notable options, 11 are puts, totaling $759,874, and 4 are calls, amounting to $349,145.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $200.0 to $300.0 for Humana over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Humana's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Humana's significant trades, within a strike price range of $200.0 to $300.0, over the past month.
<h3>Humana Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733499952_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$84.5</td>
<td>$78.2</td>
<td>$80.3</td>
<td>$200.00</td>
<td>$128.4K</td>
<td align="right">31</td>
<td align="right">17</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$84.2</td>
<td>$78.2</td>
<td>$80.3</td>
<td>$200.00</td>
<td>$120.4K</td>
<td align="right">31</td>
<td align="right">40</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$21.2</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$275.00</td>
<td>$108.0K</td>
<td align="right">47</td>
<td align="right">391</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$20.2</td>
<td>$20.0</td>
<td>$20.2</td>
<td>$275.00</td>
<td>$90.9K</td>
<td align="right">47</td>
<td align="right">125</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$20.9</td>
<td>$19.9</td>
<td>$20.0</td>
<td>$275.00</td>
<td>$88.0K</td>
<td align="right">47</td>
<td align="right">183</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
After a thorough review of the options trading surrounding Humana, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Humana Standing Right Now?</h3>
<ul>
<li>With a trading volume of 216,782, the price of HUM is down by -1.21%, reaching $279.64.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 48 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Humana with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

7 Investments To Avoid In 2025

As of Jan. 7, 2025, UnitedHealth Group is the country's most valuable insurance company, with a market cap of $473 billion.

Visualizing America's $1.7 Trillion Insurance Industry

In a report released yesterday, Lance Wilkes from Bernstein maintained a Buy rating on Humana (HUM – Research Report), with a price target of $322....

Bernstein Remains a Buy on Humana (HUM)

UnitedHealth, CVS Health made top picks at Piper Sandler on Medicare rating proposal

UnitedHealth posts rare quarterly miss amid rising medical expenses

Earnings Gains Anticipated In 7 S&P 500 Sectors, Led By Communication Services

UnitedHealth CEO: American healthcare needs to be "less complex and less confusing'

Columbia Select Large Cap Value Fund Q4 2024 Commentary

Alignment Healthcare is latest to sue Medicare over Star Ratings

Obamacare enrollments exceed 24M in 2025, a record high

AAPL

AIRR

ALHC

AMAT

BACRP

BOIL

CNRG

COST

CRAK

CVNA

DNNGY

DUSL

EPAM

FCOM

FENY

FIDU

FILL

FMAT

FSTA

FTXN

FTXR

GOOG

GOOGL

GRNTF

HDRO

IDRV

JJETF

KARS

KNCT

KOLD

MAGS

MSFT

MSTLW

OILK

OLOXF

PLTR

PLUG

PSCC

PSCE

PSCI

PSCM

QCOM

RBLD

ROKT

RSPC

RSPG

RSPM

RSPN

RSPS

SAIC

SIXG

SOLR

USAI

USOI

VWDRY

VWSYF

WFCNP

Press Releases

Humana Names Japan Mehta as Chief Information Officer

Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Humana Inc. - HUM

Humana Earns Equality 100 Award in Human Rights Campaign Foundation's 2025 Corporate Equality Index

Humana Inc. to Release Fourth Quarter 2024 Results on February 11, 2025

HUMANA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humana Inc. - HUM

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

HealthEquity

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Piper Sandler

Truist Securities

Morgan Stanley

B of A Securities

TD Cowen

水曜日、Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) は、1株あたり6.96ドルの調整後EPSを報告し、これは1年前の1株あたり8.94ドルから減少しており、<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">5.85ドルのコンセンサス</a>を上回る結果となった。
同社は、「この業績は、私たちのメディケア・アドバンテージ事業における予想を上回る収益、加えて有利なクレーム開発と予定よりも低い運用費用（そのうちの一部は性質上のタイミングを考慮しています）が原因です」と説明した。
同社は2754億ドルの売上高を報告し、これは1年前の2675億ドルから上昇し、<a href="https://www.benzinga.com/pressreleases/24/07/b40062566/humana-reports-second-quarter-2024-financial-results-affirms-full-year-adjusted-2024-financial-gui" target="_blank" rel="noreferrer noopener">2851億ドルのコンセンサスを上回る結果となった。</a>
この売上高の増加は、1人あたりのメディケア保険料の上昇、メディケア・アドバンテージおよび州政府提供の契約の会員数増加によるもの。
「今期の売上は、予想の少し上回る結果となりました。これは、予想を上回る会員数の成長と予想をわずかに上回るメンバーリスクスコアという2つのポイントが原因です」とHumanaの経営陣は準備されたコメントで述べました。
Humanaは、2四半期末において、医療総会員数が1,630万人となり、1年前の1,713万人から減少した。
メディケア・アドバンテージの会員数は、1年前の5,270,000人から、5,620,000人に増加した。
ベネフィットレシオは、1年前の86.3％から89.0％に増加し、有利なクレーム開発と予想をわずかに上回るメンバーリスクスコアの結果となっている。この有利性は、MAのネット入院費の増加により部分的に相殺されている。
Humanaは、同四半期において有利なクレーム開発を経験し、主に入院単位コストの低下、観察入院の増加、およびクレームの回収の増加が原因。
この有利性は、四半期後半において予想を超える入院回数の増加（これは四半期の後半の期間において予想を上回る結果となった）により一部相殺されている。
見通し：Humanaは2024年までの個別のメディケア・アドバンテージの年次会員数の成長予測を75,000人から<a href="https://www.benzinga.com/news/earnings/24/04/38405775/humana-boosts-medicare-advantage-membership-2024-forecast-as-q1-earnings-performance-exceeds-expect" target="_blank" rel="noreferrer noopener">新たなターゲットの225,000人</a>に引き上げた。
同社は、コンセンサスの2024年調整後EPSが1株あたり20.31ドルに対し約16.00ドルとしている。Humanaは、2024年における保険セグメントのベネフィットレシオは約90％になると予想している。
「2025年を展望すると、私たちは持続可能な利益成長を支援するために、エンタープライズ全体での成長と生産性のさらなる実現に焦点を当てています」とHumanaは<a href="https://www.benzinga.com/news/large-cap/24/04/38413321/humana-withdraws-its-already-lowered-2025-profit-guidance" target="_blank" rel="noreferrer noopener">発表しています</a>。
株価動向：水曜日の最新チェックでHUM株は1株378.97ドルで6.32％下落している。
次の記事:
<ul>
<li><a href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" target="_blank" rel="noreferrer noopener">FTCの調査、CVSヘルス、UnitedHealthを含む少数の薬局福祉管理者による反競争行為を明らかに</a>。</li>
</ul>
写真：T. Schneider / シャッターストックより

Comments

Humana

ニュース

最新ニュース Humana (NYSE:HUM) 株価情報

水曜日, 7 31, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル